Pharmaceutical Technology7d
Opzelura by Incyte for Unspecified Dermatological Disorders: Likelihood of Approval
Opzelura is under clinical development by Incyte and currently in Phase II for Unspecified Dermatological Disorders.
Incyte: Multiple Drug Launches Bode Well For Future Growth
Discover why Incyte's strong growth trajectory and upcoming product launches make it an attractive investment with a ...
pharmaphorum3y
FDA sets April date for verdict on Incyte's vitiligo drug
Opzelura is a topical version of Incyte's oral drug Jakafi/Jakavi, which is FDA approved for myelofibrosis, polycythaemia vera and graft-versus-host-disease, and has been billed as a major growth ...
pharmaphorum5d
Incyte leads JAK push into eczema as FDA clears Opzelura cream
The FDA has approved Incyte's Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only topical JAK inhibitor registered in the US. Opzelura (ruxolitinib ...
Hosted on MSN1mon
Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects
Net product revenue from Jakafi represents approximately 70% of Incyte’s total revenue, while sales from Opzelura contribute about 10%. The additional 20% is generated from royalty revenues.